Wedbush reiterates Outperform rating on Telix Pharmaceuticals, $22 price target

Wedbush reiterated their Outperform rating on Telix Pharmaceuticals's stock with a price target of $22.00.The price target implies an upside of 36.8% from the Sep 23 close of $16.08.Key takeaways from the analyst noteStrategic Acquisition of ITM: Telix's acquisition of ITM for $1.65 billion enhance…